
|Videos|June 4, 2021
Pipeline: Presbyopia treatment to finish Phase 3 late 2021
Orasis Pharmaceuticals drop in development for treating presbyopia
Advertisement
Orasis Pharmaceuticals CEO Elad Kedar says the company is looking to achieve a balance of safety, efficacy, and comfort with its drop in development for treating presbyopia. He says Phase 3 studies should finish at the end of 2021.
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
What Yuvezzi brings to the optometrist's clinical toolkit with Dr Derek Cunningham
2
The Vision Council report shows optical industry value growth amid lower volumes in 2025
3
Early SPECTRUM results outline week 8 real-world outcomes with aflibercept 8 mg
4
Higher head elevation during sleep may be associated with higher IOP, study suggests
5




























